Inactive Instrument

Press Releases Amryt Pharma plc London S.E.

Equities

GB00BKB1MS30_GB

GB00BKLTQ412

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy	Feb. 05	AQ
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma	Nov. 10	AQ
2022 for Chiesi, The Group's international growth continues	23-04-12	AQ
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc	23-04-12	GL
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc	23-04-12	GL
2022 for Chiesi: The Group’s international growth continues	23-04-11	AQ
Amryt Pharma Plc - High Court of Justice of England and Wales Sanctions Scheme of Arrangement	23-04-04	AQ
High Court of Justice of England and Wales Sanctions Scheme of Arrangement	23-04-03	GL
High Court of Justice of England and Wales Sanctions Scheme of Arrangement	23-04-03	AQ
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici	23-03-22	GL
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT	23-02-24	BU
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023	23-02-16	GL
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023	23-02-16	AQ
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT	23-01-10	BU
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc	23-01-08	AQ
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc	23-01-08	GL
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH	23-01-05	GL
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors	22-12-19	GL
European Commission approves Mycapssa® for the treatment of Acromegaly	22-12-05	GL
Amryt Announces New Patent for Mycapssa®	22-11-30	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Amryt Pharma plc London S.E.

Equities

GB00BKB1MS30_GB

GB00BKLTQ412

Press Releases

Filters